Andrew Berens

Work

Analyst Andrew Berens works at LEERINK and is focused on Healthcare, ´╗┐Basic Materials sectors with 420 price targets and ratings documented since 2014 spanning on 31 stocks. Previously, Andrew Berens worked at MORGAN STANLEY. Analyst's average stock valuation to be materialised ratio is 49.72% with an average time for price targets to be met of 155.63 days.

Most recent stock forecast was given on BGNE, BeiGene, Ltd at 20-Jan-2023.

Andrew Berens best performing recommendations are on EPZM (EPIZYME, INC).
The best stock recommendation documented was for AGIO (AGIOS PHARMACEUTICALS, INC) at 2/23/2022. The price target of $30 was fulfilled within 2 days with a profit of $2.45 (8.89%) receiving and performance score of 44.46.

Average potential price target upside

AGIO AVEO BGNE BPMC DCPH EPZM FMTX GPRE INCY MRTX SGEN ZNTL ZYME AZN CLVS GILD GWPH HOOK ARVN GBT ICPT MRUS OCUL RLYP CGEM CMPX GLUE TNGX TPTX NRIX COGT

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Sell

32

$1.28 (4.17%)

16

2 months 12 days ago

4/6 (66.67%)

$-3.45 (-9.48%)

149

Buy

37

$6.28 (20.44%)

33

5 months 24 days ago

8/14 (57.14%)

$11.15 (32.17%)

54

Buy

96

$65.28 (212.50%)

96

10 months 26 days ago

0/6 (0%)

$53.67 (151.78%)

Buy

67

$36.28 (118.10%)

61

11 months 4 days ago

7/12 (58.33%)

$25.77 (60.69%)

248

Buy

44

$13.28 (43.23%)

52

11 months 13 days ago

9/15 (60%)

$15.65 (33.73%)

157

Show more analysts
AGIO AVEO BGNE BPMC DCPH EPZM FMTX GPRE INCY MRTX SGEN ZNTL ZYME AZN CLVS GILD GWPH HOOK ARVN GBT ICPT MRUS OCUL RLYP CGEM CMPX GLUE TNGX TPTX NRIX COGT